# Nora Feeney

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/nora-feeney/

## Facts

| Field | Value |
| --- | --- |
| Citations | 2,373 |
| Field | Cancer Genomics and Diagnostics |
| h-index | 10 |
| i10-index | 10 |
| Last Known Institution | Dana-Farber Cancer Institute |
| OpenAlex ID | https://openalex.org/A5017950907 |
| Works | 42 |

## Researcher papers

- [Assessment of Resistance Mechanisms and Clinical Implications in Patients With<i>EGFR</i>T790M–Positive Lung Cancer and Acquired Resistance to Osimertinib](https://scholariq.org/papers/assessment-of-resistance-mechanisms-and-clinical-implications-in-patients-with-i/)
- [Prospective Validation of Rapid Plasma Genotyping for the Detection of<i>EGFR</i>and<i>KRAS</i>Mutations in Advanced Lung Cancer](https://scholariq.org/papers/prospective-validation-of-rapid-plasma-genotyping-for-the-detection-of-i-egfr-i/)
- [False-Positive Plasma Genotyping Due to Clonal Hematopoiesis](https://scholariq.org/papers/false-positive-plasma-genotyping-due-to-clonal-hematopoiesis/)
- [Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium](https://scholariq.org/papers/ultra-deep-next-generation-sequencing-of-plasma-cell-free-dna-in-patients-with/)
- [Amplicon-based next-generation sequencing of plasma cell-free DNA for detection of driver and resistance mutations in advanced non-small cell lung cancer](https://scholariq.org/papers/amplicon-based-next-generation-sequencing-of-plasma-cell-free-dna-for-detection/)
- [Multiparametric profiling of non–small-cell lung cancers reveals distinct immunophenotypes](https://scholariq.org/papers/multiparametric-profiling-of-non-small-cell-lung-cancers-reveals-distinct/)
- [A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in <i>EGFR</i> -Mutant Non–Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial](https://scholariq.org/papers/a-prospective-evaluation-of-circulating-tumor-cells-and-cell-free-dna-in-i-egfr/)
- [Discrimination of Germline <i>EGFR</i> T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer Patients](https://scholariq.org/papers/discrimination-of-germline-i-egfr-i-t790m-mutations-in-plasma-cell-free-dna/)
- [OA 09.02 Osimertinib Resistance Mediated by Loss of EGFR T790M Is Associated with Early Resistance and Competing Resistance Mechanisms](https://scholariq.org/papers/oa-09-02-osimertinib-resistance-mediated-by-loss-of-egfr-t790m-is-associated/)
- [Abstract CT046: Phase I dose escalation study of the CDK4/6 inhibitor palbociclib in combination with the MEK inhibitor PD-0325901 in patients with <i>RAS</i> mutant solid tumors](https://scholariq.org/papers/abstract-ct046-phase-i-dose-escalation-study-of-the-cdk4-6-inhibitor-palbociclib/)
- [Abstract 4112: Overgrowth of competing resistance mechanisms, such as an acquired KRAS mutation, underlies a poor prognosis subtype of acquired resistance to osimertinib in T790M-positive NSCLC](https://scholariq.org/papers/abstract-4112-overgrowth-of-competing-resistance-mechanisms-such-as-an-acquired/)

## Researcher topics

- [Cancer Genomics and Diagnostics](https://scholariq.org/topics/cancer-genomics-and-diagnostics/)
- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Chronic Lymphocytic Leukemia Research](https://scholariq.org/topics/chronic-lymphocytic-leukemia-research/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)

## Researcher university

- [Dana-Farber Cancer Institute](https://scholariq.org/institutions/dana-farber-cancer-institute/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.